Get started
ELI LILLY COELI LILLY COELI LILLY CO

ELI LILLY CO

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

LLYC trade ideas

LLY -- Does the BBTrend indicator really work?LLY has been a very strong stock over the past year -- obviously. But when the new BBTrend indicator is viewed, does it work or is it BS? My opinion is that it is BS. The only indicated substantial downtrend immediately follows an earnings Gap Up. In the several days following the gap, nothing trends downward. Now look at the major uptrend (by BBTrend indicator) in March and April this year. I'd call it a non-trending flat period. When the BBTrend indicator is barely positive, in May and June, is the strongest uptrend of the chart. So is BBTrend working or is it just BS? What is your experience with this new indicator?
NYSE:LLY
by tobyz7
Riding the Wave or Reaching the Crest?Recent news highlights that the Lilly Endowment sold over $150 million worth of shares. While significant insider selling could be seen as a bearish signal, it’s important to note that this does not necessarily reflect the operational performance or future outlook of the company. Investors should consider both the strategic aspects of such sales and the broader market context. The earnings report due in 59 days is critical. With strong performance in recent quarters and a solid revenue forecast, any positive surprises could further fuel the stock’s ascent. Short-Term Outlook: Price Target: Based on the current momentum and technical indicators, a short-term price target is set at $870, contingent upon breaking the $856.05 resistance level. Trading Strategy: For traders looking to capitalize on this trend, consider going long at the current levels with a stop loss placed just below the 10-day EMA at $785 to mitigate downside risk. If the price breaches $856.05 with strong volume, an aggressive target towards $900 could be pursued. Long-Term Outlook: Price Target: Given the bullish indicators and historical performance, a longer-term target of $920 is speculative yet achievable if the bullish trend sustains post-earnings. Trading Strategy: Long-term investors might consider maintaining their positions while setting a trailing stop loss to protect gains against potential market volatility or a sectoral pullback. Shorting Strategy: When to Short: If RSI and Stochastic levels remain in the overbought zone and price action fails to break above the resistance at $856.05, short positions could be considered. Stop Loss and Targets: Set an initial stop loss at $870 to cover the short in case of a breakout. A potential target for the short could be around the $820-$800 range, aligning with recent support levels. Eli Lilly & Company showcases a compelling bullish case with robust technical support. However, the overbought conditions and strategic insider selling warrant cautious optimism. Investors should closely monitor the upcoming earnings report and market reactions to pivot their strategies accordingly. The current analysis suggests a primary bullish bias with well-defined entry and exit points to optimize risk-reward dynamics in the volatile pharmaceutical sector.
NYSE:LLY
by AxiomEx
BUY LLYInvesting differs from trading as it focuses on long-term growth and sustainability of assets rather than quick gains. An investment idea involves committing money to ventures, projects, or assets expected to grow in value over time, such as stocks, bonds, or real estate. Investing requires understanding the fundamental factors that drive growth and stability. It involves detailed analysis of opportunities, like evaluating a company's financial health and potential for innovation, to minimize risk and maximize long-term gains.
NYSE:LLYLong
by boye369
ELI LILLY Preparing for the final buy opportunity.Eli Lilly is on a very steady bullish technical outlook on the 1D timeframe (RSI = 62.145, MACD = 9.380, ADX = 18.580) as it has been trading inside a Channel Up since January 2023. The current bullish vessel within this pattern is a Rising Wedge. As you can see, the two Wedges prior have a last break under the 1D MA50 before rallying to a HH at the top of the Channel Up. The 1D RSI has already crossed over its LH trendline so every pullback that comes in the next 2 weeks, is in our opinion the last buy opportunity. Our target is approximatelly a +45% rise (TP = 1000) which is the rise that all bullish structures prior experienced. See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
LLY - watch the behavior above $800Round numbers have psychological importance to market participants. They often initially act as a barrier. Once cleared they can become support or... a distant location in the rearview mirror. For reference, notice LLY's consolidation below 600 and how it took off after clearing it. A full candle close above 800 implies continuation. The next area of interest for me is the $830 0.786 of the fib extension from the February to March move. Getting above that will make things interesting. Note that the fib time zones have been moderately predictive, but that trend has respected fib fan pretty tightly. Simply remaining within the current channel is a strong opportunity. This is my largest position and a long-term hold. Invalidation of the current uptrend. It would take a move below ~752 to have me looking at a secondary downtrend, and a move below 720 to have me taking funds off of the table. If playing the break above this level on a shorter time frame, I'd keep a stop as tight as ~783.
NYSE:LLYLong
by Ben_1148x2
2
Eli Lilly's Stock Surges 4.77% on Weight-Loss Wonder DrugEli Lilly & Company (NYSE: NYSE:LLY ) has sent shockwaves through the pharmaceutical industry with the meteoric success of its weight-loss drug Zepbound, propelling the company's stock to new heights despite a mixed first-quarter performance. With sales of Zepbound surpassing Wall Street's projections by a staggering margin, Eli Lilly has raised its sales outlook for the year, overshadowing slight revenue dips from other key products. Zepbound's Triumph and Guidance Boost: In a remarkable turn of events, Zepbound emerged as the star performer in Eli Lilly's ( NYSE:LLY ) portfolio, surpassing sales forecasts by a substantial margin. With first-quarter sales reaching $517.4 million, well above the expected $373 million, Zepbound's success has prompted Eli Lilly to raise its sales guidance for the year by a staggering $2 billion. This unexpected surge in demand for the weight-loss drug has underscored Eli Lilly's position as a frontrunner in the pharmaceutical industry and has reignited investor confidence in the company's growth prospects. Challenges and Opportunities in the Diabetes Market: While Zepbound's success has captured headlines, Eli Lilly ( NYSE:LLY ) faces challenges in its diabetes portfolio, particularly with drugs like Mounjaro and Trulicity. Despite a surge in sales for Mounjaro, both drugs fell short of analyst expectations, highlighting the competitive landscape in the diabetes market. However, with plans to expand production significantly in the second half of the year, Eli Lilly remains optimistic about its ability to meet the growing demand for diabetes treatments and capitalize on emerging opportunities in the market. Analyst Insights and Market Response: Analysts have offered mixed assessments of Eli Lilly's performance, with some highlighting the company's robust guidance raise and the continued strength of Zepbound, while others have raised concerns about softer sales in the GLP-1 franchise. However, overall sentiment remains positive, with analysts reaffirming their bullish outlook on Eli Lilly's stock and emphasizing the company's strategic initiatives to drive growth and innovation. Looking Ahead: As Eli Lilly ( NYSE:LLY ) charts its course forward, all eyes are on the continued success of Zepbound and the company's ability to navigate challenges in the diabetes market. With a bolstered sales outlook and a commitment to expanding production capacity, Eli Lilly ( NYSE:LLY ) is poised to capitalize on evolving consumer preferences and emerging opportunities in the pharmaceutical landscape.
NYSE:LLYLong
by DEXWireNews
NYSE > short > LLY Based on my graphic analysis I observe a bearish projection reaching minus 7,5% in the price of this corporation, that is; from $733 it will drop to $678. With a buy exit emerging at $777, it is worth remembering that the exact time the decline will take is unpredictable, the market will simply do its job. We can mention that it will happen within the next 15-20 days from this post! REFERENCES: * Green line: emergency exit price: $777 = -6% * Red line: selling price (position) $733 * White line: profit $678 = +7,5% However, it is important to remember that these marked lines must be respected. If the price goes up 2 to 3% after you execute the position, don't try to improvise and change everything. The movement could return to the initial direction and you will be left frustrated! "Sitting quietly and waiting for the operation to develop most of the time will allow you to earn much more money. That is, sit in the stands and enjoy the spectacle that the bull will present to you, control your emotions, since the biggest enemy of "The time to invest is yourself" As for capital management, I leave it to my personal discretion knowing that we must always have money flowing and remain firm in the market. Greetings and I hope you take advantage of this good negotiation opportunity! > Josias Baltazar.n
NYSE:LLYShort
by JARTRADING2
2
LLY, LILLY IS THIS STOCK PRICE SILLY?I hope you appreciated my rhyme. So what to say about this. One main trend line at the moment. Big support incoming at 580 to 560 range. Really big support at 108. The lines in the middle (light green and red) are fairly weak and more likely short term targets. I assume the long term targets will line up well with the gaps which are marked in orange. Orange also on RSI, which is saying be careful. Short term can take it up to 980 or so but I think the lower targets are more likely and we'll see the higher targets after trend breaks and before it starts to really drop. However, there are a lot of possibilities that can occur. The main possibility looks to be a chance of a move to 980, but more likely won't get there and might stick around 780. I really have a hard time saying what this will do and when it will top out, I could tell you more if I watched this daily, but I don't. This chart is long term price targets for the downside and the upside. Given the single trend, you'll need a new chart as more develop, feel free to message if I haven't updated after some time. I think that covers most everything. Summary. I think this stock is overvalued big time, but still has potential to keep seeing more upside in the short and mid term.
NYSE:LLY
by nicktussing77
Eli Lilly and Company (LLY) - Technical Analysis ReportEli Lilly and Company (LLY) witnessed a marginal increase in its last session, closing at $762.91, which is a 0.75% uptick from the prior close. This movement is within a tight consolidation range, hinting at indecision in the market after a notable uptrend. Volume and Momentum Indicators: The volume of 842.624K is aligned with the average, suggesting a normal activity level without significant pressure. The On-Balance Volume (OBV) stands at 1.692B, supporting the current price level with stable demand. Oscillators: Relative Strength Index (RSI): The RSI is at a neutral stance of 49.85, giving room for potential price swings in either direction without immediate overbought or oversold concerns. Moving Average Convergence Divergence (MACD): The MACD line is under the signal line with declining histograms, implying a potential bearish crossover and a slow-down in bullish momentum. Technical Patterns and Indicators: Moving Averages: Ichimoku Cloud: LLY's price action remains above the cloud, indicative of a bullish primary trend. The recent price moves close to the cloud top may signal the need for cautious bullish optimism. Fibonacci Retracement: The Auto Fibonacci Retracement tool suggests key support at the 0.618 level ($727.85). The current stabilization near the 0.236 level ($762.91) may serve as a pivot for the next price movement. Speculative Price Targets: A bullish scenario could see LLY attempting to break the resistance near the recent highs at around $780. Clearing this level may pave the way towards an optimistic target of $800, a psychological and round number resistance. Conversely, a bearish shift could lead to a retest of the $727.85 support level, aligning with the 0.618 Fibonacci retracement. A break below could see further downside towards the robust support at $700, a key psychological threshold. Conclusion: Eli Lilly and Company is exhibiting signs of consolidation with the potential to break in either direction. The neutral RSI and bearish hint from the MACD suggest that traders should be prepared for increased volatility. The proximity to the Ichimoku cloud top also adds to the necessity for vigilance. Holding above or a bounce from the Fibonacci levels could signal strength, whereas a close below could indicate a deeper retracement.
NYSE:LLY
by AxiomEx
6
Rising to $1000: LLY's potential 30% leap to $1T market capIn the complex, competitive and unpredictable pharmaceutical, Eli Lilly and Co (LLY) is a notable player that is gaining even more notoriety. The company is currently making significant strides in diabetes care and weight loss medications; however, these advancements have not come without their challenges. It has recently experienced periods of management transitions and has been managing substantial debt. Such debts were incurred to invest in research and development, notably for Weight loss drugs like Mounjaro (tirzepatide), Zepbound and Retatrutide, which are at the forefront of Eli Lilly's recent success. LLY has strategically launched a direct-to-consumer platform, "LillyDirect". This move reflects the company's adaptation to digital platforms and increased demand of their product, addressing a significant barrier nowadays in the acquisition of such drugs, particularly in the weight loss segment: buying them from a supplier that hasn't run out of stocks yet. pbs.twimg.com pbs.twimg.com
NYSE:LLYLong
by JoaoFAC01
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up. In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big technology stocks. Revenues consistently beat analysts' forecasts quarter after quarter. Institutions add small lots trying to preserve the price for future buys without any run-ups. I have done the same thing and I will continue to do so. While day trading biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are parked for growth and compounding.
NYSE:LLYLong
by AwesomeAvani
1
ELI LILLY Is a -20% correction possible?Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern: In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since LLY's parabolic move started, in mid 2018 following 3 years of consolidation. The pattern that emerged since is a 6-year logarithmic Channel Up, which since 2023 has gone extremely parabolic. The key characteristic on this long-term price action is the unique pattern that the 1W MACD forms, a Bearish Cross followed by a Bullish Cross. Four such occurrences since 2018 have caused the stock to form a Higher High top at a minimum 2 weeks and maximum 10 weeks after the Bullish Cross. Currently we are on the 3rd week since the latest 1W MACD Bullish Cross and if it extends to 10 weeks, we can technically expect the new top by April 08 2024. However, the 1st red 1W candle following the Bullish Cross on those 4 past occurrences has always been the top, or near it. Given the fact that LLY is so close to the top of the 6-year Channel Up, we can expect that a correction will start soon. The minimum correction has been -17.44% and the maximum -23.23% (2 occasions out of the 4). Also before a new long-term rally started, the price hit the 1W MA50 (blue trend-line). Long-term investors can wait for such a contact before buying again heavily Eli Lilly for a new 12-month run. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Eli Lilly Stock Soars on Robust Fourth-Quarter PerformanceEli Lilly (NYSE: NYSE:LLY ) has once again defied expectations, propelling its stock to new heights with a stellar fourth-quarter performance that surpassed even the most optimistic forecasts. The pharmaceutical giant's earnings report, released early Tuesday, showcased a remarkable surge in both revenue and adjusted earnings, fueled by the successful launch of its groundbreaking weight loss drug, Zepbound, and buoyed by robust sales of its flagship diabetes treatment, Mounjaro. Earnings Review Earnings figures reveal a standout quarter for Eli Lilly (NYSE: NYSE:LLY ), with adjusted profit soaring to $2.49 per share, significantly outpacing the consensus estimate of $2.30 per share among analysts surveyed by FactSet. This remarkable feat represents a substantial increase from the year-earlier period, where earnings stood at $2.09 per share, underscoring the company's impressive growth trajectory. Revenue Result Similarly, Eli Lilly's (NYSE: NYSE:LLY ) fourth-quarter revenue surged to $9.35 billion, marking a notable 28% increase from the same period last year and surpassing analysts' expectations of $8.95 billion. This remarkable revenue surge can largely be attributed to the stellar performance of Zepbound, the company's newly approved weight loss drug, which generated a staggering $175.8 million in sales during its inaugural quarter on the market. Analysts Views The success of Zepbound has exceeded even the loftiest projections, with analysts predicting the potential for over a billion dollars in sales within its first year alone, positioning it as a potential game-changer in the pharmaceutical industry. Moreover, with its groundbreaking mechanism of action and promising efficacy profile, Zepbound holds the potential to become one of the most significant drugs in Eli Lilly's (NYSE: NYSE:LLY ) portfolio and a major revenue driver in the years to come. The Mounjaro Meanwhile, the continued strong performance of Mounjaro, Eli Lilly's (NYSE: NYSE:LLY ) blockbuster diabetes treatment, further bolstered the company's financials, with fourth-quarter sales soaring to $2.21 billion, far surpassing analysts' expectations. This remarkable growth can be attributed to both increased demand and higher realized prices, underscoring the enduring strength of Eli Lilly's (NYSE: NYSE:LLY ) diabetes franchise. Challenges However, amidst the impressive financial results, Eli Lilly (NYSE: NYSE:LLY ) also faces challenges, notably in its diabetes portfolio, where lower prices for Trulicity and Humalog offset some of the gains from Mounjaro. Despite this setback, the company remains optimistic about its long-term prospects, buoyed by the continued success of its key products and a robust pipeline of innovative therapies. Future Outlook Looking ahead, Eli Lilly (NYSE: NYSE:LLY ) has provided a bullish outlook for the full year, with projected adjusted earnings in the range of $12.20 to $12.70 per share and revenue expected to reach $40.4 billion to $41.6 billion. These optimistic forecasts reflect the company's confidence in its ability to sustain its growth momentum and capitalize on emerging opportunities in the evolving healthcare landscape. Conclusion In conclusion, Eli Lilly's (NYSE: NYSE:LLY ) fourth-quarter performance stands as a testament to its resilience, innovation, and unwavering commitment to advancing patient care. With its groundbreaking therapies and strong financial performance, Eli Lilly (NYSE: NYSE:LLY ) is well-positioned to deliver sustained value to its shareholders while continuing to make a meaningful impact on global healthcare. As Eli Lilly (NYSE: NYSE:LLY ) prepares to engage with investors during its earnings call, all eyes will be on the company as it provides insights into its strategic priorities, pipeline progress, and plans for driving future growth. Amidst a backdrop of rapid innovation and evolving market dynamics, Eli Lilly's (NYSE: NYSE:LLY ) continued success underscores its status as a powerhouse in the pharmaceutical industry and a beacon of hope for patients worldwide.
NYSE:LLYLong
by DEXWireNews
Eli Lilly Breaks New Ground With Weight Loss Drug Offering Eli Lilly - NYSE:LLY Earnings Rep: $2.49 ✅ Exp: $2.29 - 8.45% HIGHER Revenue Rep: $9.35b ✅ Exp: $8.94b - 4.55% HIGHER Company Summary Eli Lilly is the worlds 9th largest company by market cap at $670b and they have reported positive earnings and revenue both coming in higher than expected for Q4 2023. The pharmaceutical giant booked fourth-quarter revenue of $9.35 billion, up 28% from the same period a year ago. A massive result that is reflected in the chart and pre-market surge in price per a share from €706 - €740 👀 Eli develop and manufacture a series of medications with their top drugs being for diabetes and cancer. The diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly in 2022 accounting for more than one-quarter of the company's top line, which totaled $28.5 billion. Meanwhile for 2023, Trulicity, reported $1.67 billion in revenue. That’s down 14% from the same period a year go however remains a large revenue generator. Mounjaro booked $2.21 billion in sales for the fourth quarter and remains one of the companies core diabetes products. The Q4 2023 results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early Nov 2023. Zepbound resulted in $175.8 million in sales for Q4. Analysts are expecting a minimum of $1 billion in sales for the 2024 period and some are claiming that Zepbound could become the biggest drug of all time. Do you feel that AI style narrative euphoria building here? Now more importantly, Lets check out this chart The Chart The chart here really caught my attention, its one of thee strongest long term charts I have come across and it keeps making higher double bottoms off higher moving averages. The OBV is increasing still and the support line might be a good line to watch got an entry bounce or a break down (exit) - a trigger level. PUKA
NYSE:LLYLong
by PukaCharts